Study shows how brand Rx drain Medicare

Share this article:

ProPublica has dug into Medicare prescribing patterns and the results are not good. The latest series kicked off Monday, during which reporters Charles Ornstein and Tracy Weber ran down some quick, pricey facts:

  • That the prescribing habits of 913 physicians cost taxpayers an additional $300 million in medication costs in 2011 because of their preferences for brand-name drugs over generics
  • That many of these physicians pocketed industry consulting fees
  • If these same doctors had to follow the VA's prescribing rules, Medicare could have saved $1.4 billion based on the VA's 2008 prescribing patterns for diabetes, cholesterol and blood pressure medications

Part two, which ProPublica released Wednesday, reveals doctors' reactions to the reporting duo's findings, and the sampled comments reveal frustration over the perception that "new" automatically means "better."

“We've almost glamorized the doctor who uses the latest, greatest, newest drug,” President and CEO of the American Board of Internal Medicine tells ProPublica.

“They think if a drug has been approved, it must be better,” commented Yale University School of Medicine's Joseph Ross.

“We should by and large be prescribing essentially the highest-value interventions that we can, which means, generally, generics over brand names,” said University of Alabama Department of Medicine's Seth Landefeld.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.